Improvement in survival of older adults with multiple myeloma: Results of an updated period analysis of SEER data

Oncologist

Volumn 16, Issue 11, 2011, Pages 1600-1603

  Pulte, Dianne ^a   Gondos, Adam ^a   Hermann, Brenner ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DATA BASE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; POPULATION DYNAMICS; PRIORITY JOURNAL; SURVEILLANCE EPIDEMIOLOGY AND END RESULTS DATABASE; SURVIVAL RATE; TREND STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SEER PROGRAM; SURVIVAL ANALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 82355190558     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0229     Document Type: Article

References (16)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
3. Wijermans P, Schaafsma M, Termorshuizen F et al. Phase III study of the value of thalidomide added to melphelan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 2010;28:3160-3166.
4. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
5. DCCPS, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program Limited Use Data (1973-2008). Released April, 2011 based on November 2010 submission. Bethesda. MD: National Cancer Institute, 2011. Available at www.seer.cancer.gov, accessed September 28, 2011.
6. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78:2004-2010.
7. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002;20:826-832.
8. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: Model-based period analysis. Am J Epidemiol 2006;164:689-696.
9. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 1978;31:557-560.
10. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961;6:101-121.
11. Henson DE, Ries LA. The relative survival rate. Cancer 1995;76:1687-1688.
12. Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No. 10. Bethesda, MD: National Cancer Institute, 1959.
13. Arias E. United States life tables, 2000. Natl Vital Stat Rep 2002;51:1-38.
14. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma 2006-2010. Haematologica 2009; 94:270-275.
15. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2009; 361:544.
16. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.